-
Mashup Score: 1Initial Linguistic and Cultural Validation of the Satisfaction Survey for Inflatable Penile Implant (SSIPI) in Spanish - Beyond the Abstract - 1 hour(s) ago
erectile dysfunction, inflatable penile prosthesis (IPP), Satisfaction Survey for Inflatable Penile Implant (SSIPI), better patient care for Spanish speaking individuals undergoing inflatable penile prosthesis surgery.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 10Landscape of Approved and Upcoming PSMA Imaging Agents "Presentation" - Amir Iravani - 5 hour(s) ago
At the 2025 UCSF-UCLA PSMA Conference, Amir Iravani compares FDA-approved PSMA PET agents (gallium-68 PSMA-11, DCFPyL, rhPSMA-7.3) for prostate cancer imaging. Dr. Iravani notes similar specificity and modest sensitivity for lymph node detection. He questions the need for multiple trials per agent, emphasizing quality interpretation through standardized reporting matters more than which tracer…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Landscape of approved and upcoming PSMA imaging agents. @DrAIravani @fredhutch presents at the 2025 UCSF-UCLA #PSMAConference comparing FDA-approved PSMA PET agents (gallium-68 PSMA-11, DCFPyL, rhPSMA-7.3) for prostate cancer imaging. #WatchNow > https://t.co/QsYm3KbLGV https://t.co/6NrlhDpGKG
-
-
Mashup Score: 6Unveiling the Molecular Hallmarks of Peyronie's Disease: A Comprehensive Narrative Review - Beyond the Abstract - 2 day(s) ago
Peyronie’s Disease, Molecular Hallmarks of Peyronie’s Disease, tyrosine kinase inhibitor, transforming growth factor-beta (TGF-β), Matrix metalloproteinases (MMP) enzymes, Tissue inhibitors of metalloproteinases proteins (TIMP), pirfenidone, SMAD3 phosphorylation inhibitor, fresolimumab, monoclonal antibody, inhibiting all TGF isoforms, fibroblast activation protein (FAP)-targeted chimeric antigen receptor T (CAR-T) cells, FAP-targeted CAR T-cell therapy.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
New insights into #PeyroniesDisease! A comprehensive review explores the molecular hallmarks of fibrosis, highlighting key players like TGF-β, PDGF, and MMP/TIMP imbalance. Could antifibrotic therapies & CAR-T cells offer future breakthroughs? #ReadNow > https://t.co/Ed7A2nQaLc… https://t.co/V95QKHui0E
-
-
Mashup Score: 12
Testicular cancer, Testicular germ cell tumor (TGCT), Retroperitoneal Lymph Node Dissection (RPLND), pathological lymph node staging, clinical stage (CS) II seminomatous TGCT.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Primary retroperitoneal lymph node dissection for clinical stage II seminoma: A systematic review and meta-analysis of safety and oncological effectiveness. #AuthorCommentary on UroToday > https://t.co/L7tMYN7H10 @Mehdi_Kardoust @AdityaBagrodia @kensuke_bekku @DrShariat… https://t.co/F2hRHFcWTv https://t.co/aOcpoCyWOb
-
-
Mashup Score: 19
Benign prostatic hyperplasia (BPH), lower urinary tract symptoms (LUTS), Holmium Laser Enucleation of the prostate cancer (HoLEP), Advancing Holmium Laser Enucleation, American Urological Association Symptom Score (AUASS), overactive bladder symptom score (OABSS).
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Advancing holmium laser enucleation of the prostate outcomes reporting: an assessment of patient-reported outcomes in the literature. #AuthorCommentary from @laenahines @URMCUrology. #ReadNow on UroToday > https://t.co/HVN3SeWT6j @urogoldjournal https://t.co/dXaijRjs8q
-
-
Mashup Score: 10
Oliver Sartor host Ken Herrmann to discuss tumor dosimetry findings from a VISION trial substudy examining lutetium PSMA therapy in prostate cancer patients. Dr. Herrmann presents data showing that tumor-absorbed dose per injected activity decreases significantly across treatment cycles, with approximately 60% of cumulative absorbed dose occurring in the first two cycles. He explores differences…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Tumor dosimetry in PSMA therapy: A #VISION substudy analysis. @ProfKHerrmann joins Oliver Sartor, MD discussing tumor dosimetry findings from a VISION trial substudy examining lutetium PSMA therapy in #ProstateCancer patients. #FullVideo on UroToday > https://t.co/igHM3XAkST https://t.co/eHnyrkT4Ie
-
-
Mashup Score: 2
Fecal Incontinence, Sacral neuromodulation, sacral nerve stimulation (SNS), Sacral Nerve Stimulator for Management of Fecal Incontinence, overactive bladder, InterStim™ device.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Study highlights the efficacy of MRI-compatible sacral nerve stimulators in managing fecal incontinence. Results from a multi-institutional analysis show promising outcomes for safety and quality of life. Explore the findings here > https://t.co/1bCQfqrX9d https://t.co/1A83eh8etj
-
-
Mashup Score: 0Sign up - 5 day(s) ago
UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Excited for #AUA25? Stay ahead with the latest updates, research, and highlights from the event! 🩺✨ Don't miss out on crucial insights—sign up for our exclusive newsletter coverage today and #FollowUs on #SoMe for updates throughout the conference! https://t.co/GN17FCaIS6 https://t.co/6ypiqLfpWz
-
-
Mashup Score: 5ctDNA as a Prognostic Biomarker in Bladder Cancer Treatment Decisions - Nimira Alimohamed - 6 day(s) ago
Ashish Kamat speaks with Nimira Alimohamed about the evolution of circulating tumor DNA (ctDNA) in muscle invasive bladder cancer management. Dr. Alimohamed explains that current evidence establishes ctDNA detection as strongly prognostic at multiple timepoints, with detectable ctDNA before neoadjuvant therapy, after neoadjuvant therapy, or post-surgery consistently indicating poor outcomes. She…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
ctDNA as a prognostic biomarker in #BladderCancer treatment decisions. @Nimira_A @UCalgary sits down with @UroDocAsh @MDAndersonNews to discuss the evolution of ctDNA in muscle-invasive bladder cancer management. #WatchNow > https://t.co/KmX7W8mjyI https://t.co/zuOsjnxL8U
-
-
Mashup Score: 9
Treatment options for metastatic urothelial carcinoma, cisplatin-based chemotherapy, combination enfortumab vedotin–pembrolizumab, Nivolumab as adjuvant treatment in high-risk muscle-invasive UC.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Treatment patterns and survival outcomes before and after access to immune checkpoint inhibitors for patients with metastatic #UrothelialCarcinoma: a single-center retrospective study from 2004 to 2021. Author commentary on UroToday > https://t.co/usSBcA9NVa @TapiaJC1 https://t.co/9T2XK32PWP
-
Initial linguistic and cultural validation of the satisfaction survey for inflatable penile implant (SSIPI) in Spanish. #AuthorCommentary @LjubeticMD, and Jose Miguel Flores, MD, MHA share details on UroToday > https://t.co/EvyQBKDrAi https://t.co/KtVDMnqmLV